Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
LSTA Stock Chart & Stats
$2.07
-$0.01(-0.27%)
At close: 4:00 PM EST
$2.07
-$0.01(-0.27%)
Day’s Range― - ―
52-Week Range$1.81 - $4.20
Previous CloseN/A
Volume45.87K
Average Volume (3M)34.52K
Market Cap
$18.26M
Enterprise Value$2.77M
Total Cash (Recent Filing)$19.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Feb 26, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding8,820,733
10 Day Avg. Volume57,561
30 Day Avg. Volume34,515
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.84
Price to Sales (P/S)24.82
P/FCF Ratio-1.28
Enterprise Value/Market Cap0.15
Enterprise Value/Revenue2.59
Enterprise Value/Gross Profit2.59
Enterprise Value/Ebitda-0.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEncouraging preliminary results from Cohort B of the ASCEND Phase 2b trial in metastatic pancreatic ductal adenocarcinoma.
Clinical TrialsEnrollment in the 1L cohort was completed nearly 6 months ahead of initial projections, accelerating the anticipated topline data readout to 4Q25.
Financial PerformanceLisata announced 2Q25 financial results, posting EPS of ($0.54) compared to our estimate of ($0.66) and consensus of ($0.65).
Bears Say
EarningsThe company ended the quarter with approximately $22 million in cash, which management believes can cover expenses for all ongoing and proposed trials with runway into 4Q26.
Lisata Therapeutics News
LSTA FAQ
What was Lisata Therapeutics’s price range in the past 12 months?
Lisata Therapeutics lowest stock price was $1.81 and its highest was $4.20 in the past 12 months.
What is Lisata Therapeutics’s market cap?
Lisata Therapeutics’s market cap is $18.26M.
When is Lisata Therapeutics’s upcoming earnings report date?
Lisata Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 63 days.
How were Lisata Therapeutics’s earnings last quarter?
Lisata Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.535 by $0.045.
Is Lisata Therapeutics overvalued?
According to Wall Street analysts Lisata Therapeutics’s price is currently Overvalued.
Does Lisata Therapeutics pay dividends?
Lisata Therapeutics pays a Notavailable dividend of $0.31 which represents an annual dividend yield of N/A. See more information on Lisata Therapeutics dividends here
What is Lisata Therapeutics’s EPS estimate?
Lisata Therapeutics’s EPS estimate is -0.51.
How many shares outstanding does Lisata Therapeutics have?
Lisata Therapeutics has 8,820,733 shares outstanding.
What happened to Lisata Therapeutics’s price movement after its last earnings report?
Lisata Therapeutics reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.535. Following the earnings report the stock price went down -12.34%.
Which hedge fund is a major shareholder of Lisata Therapeutics?
Currently, no hedge funds are holding shares in LSTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
LSTA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Lisata Therapeutics has made significant progress in its clinical programs and strategic partnerships, reflecting strong operational management and promising trial results. However, the need for additional capital for Phase III trials poses a significant challenge. The market's lack of response to positive developments highlights ongoing investor skepticism or broader market conditions.View all LSTA earnings summariesTechnical Analysis
Clearside Biomedical
―
Aptevo Therapeutics
―
Citius Pharmaceuticals
―
Processa Pharmaceuticals
―
Apollomics
―
Ownership Overview
7.86% Insiders
3.41% Mutual Funds
1.53% Other Institutional Investors
84.42% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---